Robblee and Harvey [80] present data on cardiovascular safety for the new acute and preventive migraine treatments, including ditans, gepants, and calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) alongside older medications like triptans and ergotamines. Here, CALCA is linked to migraine disorder.